• 首页期刊简介编委会刊物订阅专栏专刊电子刊学术动态联系我们English
引用本文:周光耀1,金玲湘1,方佩佩1,李金强2,董细芬3.耐亚胺培南鲍曼不动杆菌对3种舒巴坦复合剂耐药性的meta分析[J].中国现代应用药学,2009,(12):1046-1051.
ZHOU Guangyao1,JIN Lingxiang1,FANG Peipei1,LI Jinqiang 2,DONG Xifen3.Comparison of Activities of Three Sulbactam Complex Against Imipenem Resistant Acinetobacter Baumannii Infections: A Meta Analysis[J].Chin J Mod Appl Pharm(中国现代应用药学),2009,(12):1046-1051.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2337次   下载 1239 本文二维码信息
码上扫一扫!
分享到: 微信 更多
耐亚胺培南鲍曼不动杆菌对3种舒巴坦复合剂耐药性的meta分析
周光耀1,金玲湘1,方佩佩1,李金强2,董细芬3
作者单位
周光耀1,金玲湘1,方佩佩1,李金强2,董细芬3  
摘要:
目的 采用meta分析对现已发表的氨苄西林/舒巴坦、头孢哌酮/舒巴坦和哌拉西林/舒巴坦治疗耐亚胺培南鲍曼不动杆菌(IRAB)的文献进行综合分析,科学比较哪种抗生素的治疗效果更好。方法 全面收集IRAB对氨苄西林/舒巴坦、头孢哌酮/舒巴坦和哌拉西林/舒巴坦耐药性研究的资料,根据严格的标准筛选纳入文献,用RevMan 4.2软件进行meta分析。 结果 共有9篇文献符合纳入标准。对氨苄西林/舒巴坦和头孢哌酮/舒巴坦的耐药性分析表明,IRAB对氨苄西林/舒巴坦(62.8%)的耐药性显著高于对头孢哌酮/舒巴坦的(44.7%)(P<0.001)。对氨苄西林/舒巴坦和哌拉西林/舒巴坦的耐药性分析表明,IRAB对氨苄西林/舒巴坦(70.7%)的耐药性显著低于对哌拉西林/舒巴坦的(95.2%)(P<0.001)。综合可得,IRAB对头孢哌酮/舒巴坦的耐药性最弱,对哌拉西林/舒巴坦的耐药性最强。结论 在IRAB的治疗中,头孢哌酮/舒巴坦的敏感性高于氨苄西林/舒巴坦和哌拉西林/舒巴坦,是较好的供选抗生素。
关键词:  耐亚胺培南鲍曼不动杆菌  耐药性  氨苄西林/舒巴坦  头孢哌酮/舒巴坦  哌拉西林/舒巴坦  meta分析
DOI:
分类号:
基金项目:
Comparison of Activities of Three Sulbactam Complex Against Imipenem Resistant Acinetobacter Baumannii Infections: A Meta Analysis
ZHOU Guangyao1,JIN Lingxiang1,FANG Peipei1,LI Jinqiang 2,DONG Xifen3
Abstract:
OBJECTIVE A meta analysis was performed to decide whether ampicillin, cefoperazone or piperacillin in combination with sulbactam is better to cure imipenem resistant Acinetobacter baumannii in China. METHODS After a comprehensive electronic and manual searching according to our strict criterions, the related data were used for subsequent meta analysis using RevMan 4.2. RESULTS Total 9 papers were collected. The resistant rate of IRAB versus ampicillin/sulbactam (62.8%) was significantly higher than that of cefoperazone/sulbactam (44.7%) (P<0.001), and the resistant rate of IRAB versus ampicillin/sulbactam (70.7%) was significantly lower than that of piperacillin/sulbactam (95.2%) (P<0.001). That is to say, among the three sulbactam complex the resistant rate of IRAB versus cefoperazone/sulbactam was the highest, while the resistant rate of IRAB versus piperacillin /sulbactam was the lowest.CONCLUSION In the process of curing IRAB infections, cefoperazone/sulbactam is more sensitive than ampicillin/sulbactam and piperacillin/sulbactam, and thus is a better candidated antibiotic.
Key words:  imipenem resistant Acinetobacter baumannii  resistance  ampicillin/sulbactam  cefoperazone/sulbactam  piperacillin/sulbactam  meta analysis
扫一扫关注本刊微信